Where ADCs Fit in the EGFR+ NSCLC Treatment Paradigm

Samuel Rosner, MD, and Laura Alder, MD, review the growing role of antibody–drug conjugates (ADCs) in the treatment landscape for EGFR-mutated non–small cell lung cancer. Rosner discusses clinical data supporting the activity of this class of agents in patients with previously treated disease. Alder highlights important safety considerations, including interstitial lung disease and hematologic toxicity, that must be addressed when integrating ADCs into clinical practice.